US 12,239,617 B2
Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity
Terry Chow, Ville d'Anjou (CA)
Filed by MONTDOREX INC., Ville d'Anjou (CA)
Filed on Jul. 16, 2021, as Appl. No. 17/378,346.
Application 17/378,346 is a continuation of application No. 16/759,768, granted, now 11,103,468, previously published as PCT/CA2018/051409, filed on Nov. 8, 2018.
Claims priority of provisional application 62/587,118, filed on Nov. 16, 2017.
Prior Publication US 2021/0338607 A1, Nov. 4, 2021
Int. Cl. A61K 31/55 (2006.01); A61K 31/155 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/155 (2013.01) [A61P 35/00 (2018.01)] 12 Claims
OG exemplary drawing
 
1. A method of treating an endo-exonuclease-mediated cancer selected from one or more of colon cancer, breast cancer, cervical cancer and lung carcinoma, comprising:
inhibiting endo-exonuclease activity by administering to a patient a therapeutically effective amount of a compound having the formula:

OG Complex Work Unit Chemistry
wherein:
R3 is selected from the group consisting of:
methyl, isopropyl or isobutyl;
R4 is H, or a halogen; and
R5 (CH2)n, and wherein n is equal to an integer from 1 to 7 inclusively.